Enhancement of effects of WT1 peptide-based immunotherapy for malignant glioma.

2016 Fiscal Year Final Research Report

• Project/Area Number: 26462179
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurosurgery
• Research Institution: Osaka University
• Principal Investigator: Tsuboi Akihiro 大阪大学, 医学系研究科, 寄附講座教授 (10372608)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: ペプチドワクチン / 臨床試験 / ＷＴ１ / ヘルパーペプチド / 悪性神経膠腫 / 膠芽腫 / テモゾロミド

Outline of Final Research Achievements

We have investigated peptide based immunotherapy for malignant tumors targeting Wilms tumor 1 (WT1) that is expressed in almost malignancies including malignant glioma and has high immunogenicity. In this study, we have used not only HLA class I restricted two WT1 peptides but also HLA class II-restricted WT1 peptide (WT1 Trio Peptide) to enhance WT1 specific immune responses and performed two kinds of clinical study using the WT1 Trio Peptide for malignant glioma. One trial is WT1 Trio Peptide-vaccine for Rare Cancers. Patients with recurrent malignant glioma are enrolled in this study. The other one is Phase II clinical trial of WT1 peptide-based vaccine combined with Temozolomide for patients with newly diagnosed glioblastoma. Both studies are recruiting.

Free Research Field

癌免疫